Technology | November 01, 2012

Terumo Launches Peripheral Access System

New system facilitates smooth, reliable and precise vascular access

November 1, 2012 — Terumo Interventional Systems announced the nationwide availability of its new Pinnacle Precision Access System. The vascular access system specifically designed for smooth, efficient and reliable peripheral vascular access. It offers the only available tapered introducer needle to minimize vessel trauma, dilate the tissue and gain more precise access in difficult cases, such as those impeded by scar tissue or calcification.

“Terumo’s Pinnacle Precision Access System is one of the most innovative advancements in technology that will help us achieve success in peripheral vascular intervention, specifically where critical limb ischemia (CLI) is present,” said Jihad Mustapha, M.D., FACC, FSCAI, director of endovascular laboratories and director of cardiovascular research at Metro Heart and Vascular, Metro Health Hospital, in Wyoming, Mich. “From the tapered needle to the TIF (total integrated fit) sheath, Terumo provides a seamless transition for vascular access femorally or peripherally.”

One of the system’s most significant advantages is the elimination of procedural steps compared to alternative products. Traditionally, once access is achieved, the site is gradually enlarged to the desired French size by exchanging to a larger wire and sheath. Terumo’s new precision access system eliminates the need for both a micropuncture kit and a standard size introducer sheath. It features proven TIF technology and a new tapered 21 gauge needle that allow for a smaller, straighter and more accurate puncture to significantly reduce vessel entry site trauma and access complications.

The system was designed and developed at Terumo’s manufacturing facility in Elkton, Md. The upgraded facility combines manufacturing and new product development teams in the same geographic location to streamline research and development while maximizing manufacturing efficiencies.

For more information: www.terumois.com

Related Content

he 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent showed low rates of revascularization and compared very favorably to current standards of care.  The results were presented by Professor Thomas Zeller, M.D., University Heart Centre Freiburg, Bad Krozingen, Germany at the CX 2020 Live conference.   
News | Peripheral Artery Disease (PAD) | June 16, 2020
June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020
March 28, 2020 — People with symptomatic...
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded tria
The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot.  #VIVA #VIVA19 #VIVA2019

The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot. 

News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — Results were positive for the multicenter PROMISE I Trial represents the first human use in the U
Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA
News | Peripheral Artery Disease (PAD) | November 06, 2019
November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-elutin
FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-...
New Report Says Concept Medical Positioned to Disrupt Peripheral Market
News | Peripheral Artery Disease (PAD) | August 27, 2019
Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)...
PAD Intervention Patients on Statins Less Likely to Face Amputation
News | Peripheral Artery Disease (PAD) | August 23, 2019
Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after surgical...
Concept Medical Granted FDA Breakthrough Device Designation for MagicTouch PTA Sirolimus Coated Balloon
News | Peripheral Artery Disease (PAD) | August 14, 2019
Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug...